All In Biotech

Drug Trial Radar · NCT06886269

A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose

A Phase 1, Open-label, Mass Balance Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-VX-993 Following Single Oral Administration in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Jun 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Mar 21, 2025

Primary completion

May 17, 2025

Study completion May 17, 2025

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Mar 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the routes and rate of elimination and recovery of total radioactivity (TRA) and characterize the Pharmacokinetic (PK) of VX-993 after a single oral dose of 14C-VX-993.

Conditions

  • Pain

Interventions

  • 14C-VX-993Drug

    Solution for Oral Administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Terminal Phase Rate Constant (λz) of VX-993 in PlasmaTime frame: From Day 1 up to Day 25
  2. Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-tlast) of VX-993 in PlasmaTime frame: From Day 1 up to Day 25
  3. Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-993 in PlasmaTime frame: From Day 1 up to Day 25
  4. Apparent Clearance (CL/F) of VX-993 in PlasmaTime frame: From Day 1 up to Day 25
  5. Maximum Observed Plasma Concentration (Cmax) of VX-993 in PlasmaTime frame: From Day 1 up to Day 25
  6. Time for VX-993 to Reach Maximum Concentration (Tmax) in PlasmaTime frame: From Day 1 up to Day 25
  7. Apparent Volume of Distribution (Vz/F) (Based on the Terminal Phase) of VX-993 in PlasmaTime frame: From Day 1 up to Day 25
  8. Terminal Phase Rate Constant (λz) of Total Radioactivity (TRA) in Whole blood and PlasmaTime frame: From Day 1 up to Day 25
  9. Amount of Radioactivity Excreted (Ae) of TRA in Urine, Feces and Vomitus (if applicable)Time frame: Pre dose up to Day 25
  10. AUC0-tlast of TRA in Whole blood and PlasmaTime frame: From Day 1 up to Day 25
  11. AUC0-inf of TRA in Whole blood and PlasmaTime frame: From Day 1 up to Day 25
  12. CL/F of TRA in Whole blood and PlasmaTime frame: From Day 1 up to Day 25
  13. Renal Clearance (CLr) of TRA in Urine and FecesTime frame: Pre dose up to Day 25
  14. Cmax of TRA in Whole blood and PlasmaTime frame: From Day 1 up to Day 25
  15. Fraction (percent) of Dose Excreted Unchanged in Urine of TRATime frame: Pre dose up to Day 25
  16. Tmax of TRA in Whole blood and PlasmaTime frame: From Day 1 up to Day 25
  17. Apparent Volume of Distribution (Based on the Terminal Phase) of TRA in Whole blood and PlasmaTime frame: From Day 1 up to Day 25
  18. Amount of VX-993 and Metabolites, Expressed as a percent of TRA, in Plasma, Urine and FecesTime frame: From Day 1 up to Day 25

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion - Lincoln

    Lincoln, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.